Boston Partners Acquires 29,394 Shares of DaVita Inc. (NYSE:DVA)

Boston Partners increased its holdings in DaVita Inc. (NYSE:DVA) by 48.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,453 shares of the company’s stock after purchasing an additional 29,394 shares during the period. Boston Partners owned approximately 0.11% of DaVita worth $13,387,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of DVA. JPMorgan Chase & Co. boosted its stake in shares of DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares in the last quarter. Amundi grew its holdings in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after purchasing an additional 240,126 shares during the last quarter. KBC Group NV raised its position in shares of DaVita by 0.8% in the fourth quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after purchasing an additional 2,636 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of DaVita by 23.9% in the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock worth $47,874,000 after buying an additional 56,389 shares during the last quarter. Finally, Nordea Investment Management AB boosted its holdings in shares of DaVita by 4.9% during the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock worth $39,712,000 after buying an additional 12,339 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Trading Down 0.5 %

Shares of DVA opened at $149.06 on Friday. The stock’s 50-day moving average price is $158.63 and its 200 day moving average price is $157.49. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60. The firm has a market capitalization of $11.92 billion, a price-to-earnings ratio of 13.88, a P/E/G ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, research analysts predict that DaVita Inc. will post 10.76 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Barclays increased their target price on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Finally, Cowen reaffirmed a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.